A simple high performance liquid chromatography method for determination of rebamipide in rat urine

Dustin L Cooper,Sam Harirforoosh

doi:10.1016/j.mex.2014.06.002

Abstract

Rebamipide is a mucoprotective agent commonly used to prevent nonsteriodal anti-inflammatory drug-induced gastrointenstinal side effects [1]. Human plasma and urine analysis of rebamipide utilizing high performance liquid chromatography (HPLC) have been reported [2]. Recently, we reported on the plasma levels of rebamipide in presense or absence of celecoxib or diclofenac in rats [3] using a modified HPLC method of detection developed by Jeoung et al. [4]. To tailor the method towards use in urinary rebamipide extraction and analysis, the following modifications were made:•To compensate for high concentrations of rebamipide found in urine, a new rebamipide stock solution was prepared with a final concentration of 50,000ng/mL.•Rat urine calibration standards were obtained within the range of 50–1000ng/mL and 1000–50,000ng/mL.•Plasma samples were replaced with urine samples.

Highlights

Background informationVarious prostaglandins function to regulate and control gut health and gastrointestinal (GI) integrity [6]
Analysis of rebamipide concentrations in the urine involved preparation of rebamipide stock solution, development of low and high linear standard calibration curves to compensate for altered rebamipide concentrations noted in urine samples, use of acetonitrile and hydrochloric acid for urinary rebamipide extraction, and HPLC analysis of rebamipide using a Shimadzu HPLC system
HPLC analysis was carried out using a C18 analytical column with a flow rate of 0.5 mL/min and a fluorescent detector set at an excitation wavelength of 320 nm with an emission wavelength of 380 nm

Summary

Introduction

Background informationVarious prostaglandins function to regulate and control gut health and gastrointestinal (GI) integrity [6]. Rebamipide urine analysis was carried out using samples obtained from a previous study [5]. Analysis of rebamipide concentrations in the urine involved preparation of rebamipide stock solution, development of low and high linear standard calibration curves to compensate for altered rebamipide concentrations noted in urine samples, use of acetonitrile and hydrochloric acid for urinary rebamipide extraction, and HPLC analysis of rebamipide using a Shimadzu HPLC system. HPLC analysis was carried out using a C18 analytical column with a flow rate of 0.5 mL/min and a fluorescent detector set at an excitation wavelength of 320 nm with an emission wavelength of 380 nm.

Results

Conclusion